Your browser doesn't support javascript.
loading
A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
Tan, Tira J; Ang, W X Gladys; Wang, Who-Whong; Chong, Hui-Shan; Tan, Sze Huey; Cheong, Rachael; Chia, John Whay-Kuang; Syn, Nicholas L; Shuen, Wai Ho; Ba, Rebecca; Kaliaperumal, Nivashini; Au, Bijin; Hopkins, Richard; Li, Xinhua; Tan, Aaron C; Seet, Amanda O L; Connolly, John E; Arkachaisri, Thaschawee; Chew, Valerie; Lajam, Ahmad Bin Mohamed; Guo, Dianyan; Chew, Marvin Z W; Wasser, Martin; Kumar, Pavanish; Albani, Salvatore; Toh, Han Chong.
Afiliación
  • Tan TJ; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Ang WXG; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
  • Wang WW; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Chong HS; Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore, Singapore.
  • Tan SH; Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore, Singapore.
  • Cheong R; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Chia JW; Curie Oncology, Singapore, Singapore.
  • Syn NL; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Shuen WH; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Ba R; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Kaliaperumal N; Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Au B; Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Hopkins R; Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Li X; Singapore Clinical Research Institute (SCRI), Singapore, Singapore.
  • Tan AC; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Seet AOL; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Connolly JE; Institute of Molecular and Cellular Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Arkachaisri T; Rheumatology and Immunology Service, KK Women's and Children's Hospital, Singapore, Singapore.
  • Chew V; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
  • Lajam ABM; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
  • Guo D; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
  • Chew MZW; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
  • Wasser M; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
  • Kumar P; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.
  • Albani S; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore. salvo@duke-nus.edu.sg.
  • Toh HC; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore. toh.han.chong@singhealth.com.sg.
Nat Commun ; 13(1): 6453, 2022 10 28.
Article en En | MEDLINE | ID: mdl-36307410
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Adenocarcinoma / Vacunas contra el Cáncer Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Singapur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Adenocarcinoma / Vacunas contra el Cáncer Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Singapur